Nuo Therapeutics Inc (NUOT) 0.0145 $NUOT
Nuo Therapeutics Provides Update on Chapter 11 Bankruptcy Process and Proposed Plan of Reorganization
BusinessWire - Tue Mar 29, 4:44PM CDT
--Conference Call Scheduled for Wednesday, March 30th at 4:30 ET
Nuo Therapeutics Inc. Commences Voluntary Chapter 11 Business Reorganization
BusinessWire - Tue Jan 26, 2:06PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT) (the "Company"
announced today that it has filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company announced that it will request approval of an aggregate of approximately $9.0 million in debtor-in-possession financing from its pre-bankruptcy lenders, Deerfield Management, L.P. and certain of its affiliates. The Company will continue to operate its business as a debtor-in-possession during the reorganization and expects that substantially all of its assets will be sold pursuant to a bankruptcy court supervised process under section 363 of the Bankruptcy Code.
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/t6wjrw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview - Therapeutics Development - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development - Alvogen Korea - AnGes MG, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Hemostemix Ltd - Mesoblast Limited - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Symic Biomedical, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. - Yuyu Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/t6wjrw/peripheral
MESO: 3.80 (-0.18), AZN: 27.86 (-1.43), ATHX: 1.97 (-0.03), PRTO: 6.00 (+0.65), CELGZ: 1.42 (-0.03)
Nuo Therapeutics Announces Senior Management Change and Provides Limited Corporate Update
BusinessWire - Tue Jan 12, 7:12AM CST
Nuo Therapeutics, Inc. (OTCQX: NUOT) ("Nuo" or the "Company" , today announced that the Company has provided written notice to terminate, without cause, the employment relationship between the Company and Dean Tozer, its President and Chief Executive Officer. Also on January 8, 2016, the Board appointed the Company's Acting Chief Financial Officer, David E. Jorden, as the Company's Acting Chief Executive Officer, effective immediately.
Nuo Therapeutics Announces Execution of Third Limited Consent With Deerfield Management Through January 7, 2016
GlobeNewswire - Fri Dec 18, 4:15PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), today announced that the Company has entered into a third limited consent with Deerfield Management, L.P. and certain of its affiliates, to modify certain provisions of the credit facility agreement ("Facility Agreement" between Nuo and Deerfield, as follows:
Nuo Therapeutics Announces Appointment of Chief Restructuring Officer
GlobeNewswire - Mon Dec 14, 7:30AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), today announced that it has engaged Winter Harbor LLC to assist the company in its financial restructuring process. In connection with the engagement, Mr. Shaun Martin, a principal at Winter Harbor, has been appointed Chief Restructuring Officer of Nuo effective December 15, 2015, and will report directly to its Board of Directors. On December 4, 2015, Nuo entered into a limited consent with Deerfield Management L.P., and certain of its affiliates, which required Nuo to engage a Chief Restructuring Officer.
Lysosomal Storage Disorder Pipeline Study 2015 - 13 Companies & 24 Drug Profiles
M2 - Thu Dec 10, 10:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/jf8rhj/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - Amicus Therapeutics, Inc. - AngioChem Inc. - Fate Therapeutics, Inc. - Minoryx Therapeutics s.l. - Nimbus Therapeutics, LLC - Nuo Therapeutics, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Promosome, LLC - REGiMMUNE Corporation - Sangamo BioSciences, Inc. - Ultragenyx Pharmaceutical Inc. Drug Profiles - 2B3-201 - ALD-601 - Chaperone-ERT Combinations - Delta-tocopherol - FT-1050 - ML-SA1 - OR-02 - OR-03 - Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Recombinant Enzyme for LSD-2 Disease - Recombinant Enzyme for LSD-3 Disease - Recombinant Enzyme for LSD-4 Disease - Recombinant Enzyme for LSD-5 Disease - Recombinant Enzyme for Lysosomal Storage Diseases and Metabolic Disorders - Recombinant Enzyme for Lysosomal Storage Disorder - Recombinant Enzyme to Target LRP1 for Lysosomal Storage Disorder - RGI-5000 - SBLSD-3 - SBLSD-4 - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecules for GM1-gangliosidosis and Morquio B - Small Molecules for Lysosomal Storage Disorders - Stem Cell Therapy for Lysosomal Storage Disorder - UX-004 For more information visit http://www.researchandmarkets.com/research/jf...al_storage
FATE: 1.89 (+0.06), SGMO: 5.51 (-0.41), FOLD: 5.45 (-0.46)
Nuo Therapeutics Announces Execution of Second Limited Consent With Deerfield Management Through December 17, 2015
GlobeNewswire - Mon Dec 07, 7:30AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that on December 4, 2015, it entered into a limited consent with Deerfield Management, L.P. and certain of its affiliates, to modify certain provisions of the credit facility agreement ("Facility Agreement" between Nuo and Deerfield, as follows:
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/997zbq/coronary_artery) has announced the addition of the "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amarantus Bioscience Holdings, Inc. - AnGes MG, Inc. - AstraZeneca Plc - Bayer AG - Biosidus S.A. - Biscayne Pharmaceuticals, Inc. - Capricor Therapeutics, Inc. - Eagle Pharmaceuticals, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - Hemostemix Ltd - Human Stem Cells Institute - Juventas Therapeutics, Inc. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Lonestar Heart, Inc. - MedImmune, LLC - Merck & Co., Inc. - Miltenyi Biotec GmbH - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. - The Medicines Company - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/99...ary_artery
CAPR: 4.18 (-0.20), PSTI: 1.29 (-0.07), LLY: 74.33 (+0.39), EGRX: 36.37 (-3.03), GILD: 80.47 (-2.90), AZN: 27.86 (-1.43), MRK: 55.88 (-1.80)
Nuo Therapeutics Announces Execution of Limited Consent With Deerfield Management Through December 4, 2015
GlobeNewswire - Thu Nov 12, 7:24PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the execution as of November 11, 2015 of a limited consent with Deerfield Management, L.P. and certain of its affiliates pursuant to which the Deerfield Facility Agreement was modified to provide that:
Nuo Therapeutics Announces 3rd Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 7:24PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today reported financial results for the third quarter ended September 30, 2015 and provided a strategic and operational update.
Nuo Therapeutics to Hold Third Quarter 2015 Conference Call on Friday, November 13 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Nov 04, 7:30AM CST
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of market.
Nuo Therapeutics Responds to Favorable CMS Hospital Outpatient Payment Final Ruling for Aurix System
GlobeNewswire - Mon Nov 02, 7:31AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the Aurix(TM) System reimbursement rate under the Hospital Outpatient Prospective Payment System (HOPPS) for the calendar year 2016 has been published by the Centers for Medicare and Medicaid Services (CMS). Aurix was placed in Ambulatory Payment Classification (APC) 5054 (Level 4 Skin Procedures) and will be reimbursed at a national average rate of $1,411 per application effective January 1, 2016. In the text of the ruling, CMS commented they believe the geometric mean cost of the services underlying Aurix is comparable to the geometric mean cost of APC 5054.
Nuo Therapeutics Executes Amended Licensing Agreement With Arthrex
GlobeNewswire - Tue Oct 20, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced it has executed an amended and restated license agreement with Arthrex, Inc., through which Arthrex has exercised its right to assume responsibility for the manufacture and supply of the Company's Angel(R) Concentrated Platelet Rich Plasma System (Angel), an option granted and contemplated in the original license agreement. Additionally, Nuo is retaining the underlying patents to Angel while transferring the as-defined product registration rights and obligations.
Global Intermittent Claudication Pipeline Review 2015 - 6 Companies & 6 Drug Profiles
M2 - Mon Oct 05, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/678332/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Intermittent Claudication, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intermittent Claudication and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cytokinetics, Inc. - DNAVEC Corporation - Kowa Company, Ltd. - LTT Bio-Pharma Co., Ltd. - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. Drug Profiles - ALD-301 - DVC1-0101 - K-134 - LT-0101 - PLX-PAD - tirasemtiv For more information visit http://www.researchandmarkets.com/research/67...termittent
CYTK: 9.04 (+0.05), PSTI: 1.29 (-0.07)
Global Stem Cell Umbilical Cord Blood Market 2015-2019
M2 - Thu Sep 24, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5r9dpb/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood Market 2015-2019" report to their offering. Public awareness of stem cell UCB banking is increasing due to the various awareness programs conducted. This is done with the motive of making people aware of the potential benefits of cord blood banking. It will result in social and economic benefits as well. At the events, the idea is to educate people about the importance of cord blood banking. This is vital because it can help in the improvement of the quality of life of many patients suffering from life-threatening diseases. Companies such as Americord and Viacord are promoting July as National Stem Cell Awareness month. Similarly, Precious Cells surveyed 1,000 families in UK with children under the age of 10, as part of the National Stem Cell Awareness Day on October 8, 2014. To increase the awareness of cord blood banking, Save the Cord Foundation is partnering with Bioinformant. Also, LifeCell is creating awareness among in India about the need for umbilical cord stem cell banking. These programs help in promoting awareness for present and future stem cell treatments. According to the report, UCB stem cells prove to be an effective treatment option for more than 80 diseases, such as cancer, immunodeficiency disorders, and blood disorders. Many of these diseases, which have no cure, can be treated effectively with the use of stem cells obtained from the umbilical cord. These stem cells travel to the site of damage and identify the defective cells. They then initiate a healing process and are thus used in the treatment. Since they are derived from the same individual, the risk of rejection can also be eliminated. Research is being carried out for the development of UCB stem cells as an effective treatment option for diseases such as diabetes, Alzheimer's disease, brain tumor, and heart failure. They can thus be used as a successful mode of treatment for many of life-threatening diseases. Key Topics Covered - Executive Summary - Introduction - Process of Collection, Processing, and Storage of Cord Blood Cells - Facts: Cord Blood Units - US FDA Approved Stem Cell UCB Product - Pipeline Analysis - Market Landscape - Market Segmentation by Application - Market Segmentation by Storage - Harmonization of Biobanking - Market Segmentation by End-user - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Global Stem Cell UCB Market: Key Takeaways - Key Vendor Analysis Companies Mentioned - Athersys - Caladrius Biosciences - Celgene - CHA Bio & Diostech - Cytori Therapeutics - Mesoblast - Nuo Therapeutics - Ocata Therapeutics - Opexa Therapeutics - Osiris Therapeutics - Pluristem Therapeutics - Teva Pharmaceuticals - United Therapeutics For more information visit http://www.researchandmarkets.com/research/5r..._stem_cell
OCAT: 8.47 (+0.01), OPXA: 4.00 (+0.13), PSTI: 1.29 (-0.07), CYTX: 2.02 (+0.02), UTHR: 102.11 (-3.17), OSIR: 5.18 (-0.32), CLBS: 0.55 (+0.02), CELGZ: 1.42 (-0.03)
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015
M2 - Wed Sep 23, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mlsnz6/chronic_coronary) has announced the addition of the "Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Human Stem Cells Institute - Lacer, S.A. - Nuo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/ml...c_coronary
Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019 - Key Vendors are AstraZeneca, Bayer, Eli Lilly, Novartis, Pfizer & Sanofi
M2 - Thu Sep 17, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6skk9g/global_ischemic) has announced the addition of the "Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019" report to their offering. The global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019. The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. The market has huge growth opportunities for vendors because of the growing population of individuals with IHD. To capture maximum market shares and expand the focus area, vendors are investing more on R&D. According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases. The people with diabetes are three to four times more likely to develop CVDs than people without diabetes. Further, the report states that the availability of effective surgical treatments and the use of catheter based interventions pose a challenge to the growth of market. The need for specific therapeutics at the later stages of the disease leads to the increased reliance on stents and surgeries. IHD includes: - Angina pectoris - Myocardial infarction. Key Vendors - AstraZeneca - Bayer - Eli Lilly - Novartis - Pfizer - Sanofi Other Prominent Vendors - Actelion - Amgen - Baxter - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi-Sankyo - Eisai - F.Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Human Stem Cells Institute - Janssen Pharmaceuticals - Juventas Therapeutics - Lacer - Merck - Nuo Therapeutics - Ono Pharmaceutical - Pharmahungary Group - Resverlogix - Takeda Pharmaceutical Company - Taxus Cardium - The Medicines Company - United Therapeutics For more information visit http://www.researchandmarkets.com/research/6s...l_ischemic
GILD: 80.47 (-2.90), UTHR: 102.11 (-3.17), MRK: 55.88 (-1.80), AMGN: 146.45 (-5.82), LLY: 74.33 (+0.39), GSK: 40.80 (-1.76), BMY: 70.61 (-2.03), NVS: 77.10 (-3.57)
Nuo Therapeutics Launches Educational Program to Support Wound Care Centers in Transition to ICD-10
GlobeNewswire - Mon Sep 14, 7:30AM CDT
First Webinar for Wound Care Professionals to be held September 15 at 1:00 p.m. Eastern on http://www.woundsresearch.com/ICD10
Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 5.64 (-0.43), PFE: 33.97 (-0.62), AZN: 27.86 (-1.43), AMGN: 146.45 (-5.82), LLY: 74.33 (+0.39), STML: 6.99 (-0.11)
Nuo Therapeutics Provides Update on Chapter 11 Bankruptcy Process and Proposed Plan of Reorganization
BusinessWire - Tue Mar 29, 4:44PM CDT
--Conference Call Scheduled for Wednesday, March 30th at 4:30 ET
Nuo Therapeutics Inc. Commences Voluntary Chapter 11 Business Reorganization
BusinessWire - Tue Jan 26, 2:06PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT) (the "Company"
announced today that it has filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company announced that it will request approval of an aggregate of approximately $9.0 million in debtor-in-possession financing from its pre-bankruptcy lenders, Deerfield Management, L.P. and certain of its affiliates. The Company will continue to operate its business as a debtor-in-possession during the reorganization and expects that substantially all of its assets will be sold pursuant to a bankruptcy court supervised process under section 363 of the Bankruptcy Code. Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/t6wjrw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview - Therapeutics Development - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development - Alvogen Korea - AnGes MG, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Hemostemix Ltd - Mesoblast Limited - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Symic Biomedical, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. - Yuyu Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/t6wjrw/peripheral
MESO: 3.80 (-0.18), AZN: 27.86 (-1.43), ATHX: 1.97 (-0.03), PRTO: 6.00 (+0.65), CELGZ: 1.42 (-0.03)
Nuo Therapeutics Announces Senior Management Change and Provides Limited Corporate Update
BusinessWire - Tue Jan 12, 7:12AM CST
Nuo Therapeutics, Inc. (OTCQX: NUOT) ("Nuo" or the "Company"
, today announced that the Company has provided written notice to terminate, without cause, the employment relationship between the Company and Dean Tozer, its President and Chief Executive Officer. Also on January 8, 2016, the Board appointed the Company's Acting Chief Financial Officer, David E. Jorden, as the Company's Acting Chief Executive Officer, effective immediately. Nuo Therapeutics Announces Execution of Third Limited Consent With Deerfield Management Through January 7, 2016
GlobeNewswire - Fri Dec 18, 4:15PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), today announced that the Company has entered into a third limited consent with Deerfield Management, L.P. and certain of its affiliates, to modify certain provisions of the credit facility agreement ("Facility Agreement"
between Nuo and Deerfield, as follows: Nuo Therapeutics Announces Appointment of Chief Restructuring Officer
GlobeNewswire - Mon Dec 14, 7:30AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), today announced that it has engaged Winter Harbor LLC to assist the company in its financial restructuring process. In connection with the engagement, Mr. Shaun Martin, a principal at Winter Harbor, has been appointed Chief Restructuring Officer of Nuo effective December 15, 2015, and will report directly to its Board of Directors. On December 4, 2015, Nuo entered into a limited consent with Deerfield Management L.P., and certain of its affiliates, which required Nuo to engage a Chief Restructuring Officer.
Lysosomal Storage Disorder Pipeline Study 2015 - 13 Companies & 24 Drug Profiles
M2 - Thu Dec 10, 10:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/jf8rhj/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 2-BBB Medicines BV - Amicus Therapeutics, Inc. - AngioChem Inc. - Fate Therapeutics, Inc. - Minoryx Therapeutics s.l. - Nimbus Therapeutics, LLC - Nuo Therapeutics, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Promosome, LLC - REGiMMUNE Corporation - Sangamo BioSciences, Inc. - Ultragenyx Pharmaceutical Inc. Drug Profiles - 2B3-201 - ALD-601 - Chaperone-ERT Combinations - Delta-tocopherol - FT-1050 - ML-SA1 - OR-02 - OR-03 - Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Recombinant Enzyme for LSD-2 Disease - Recombinant Enzyme for LSD-3 Disease - Recombinant Enzyme for LSD-4 Disease - Recombinant Enzyme for LSD-5 Disease - Recombinant Enzyme for Lysosomal Storage Diseases and Metabolic Disorders - Recombinant Enzyme for Lysosomal Storage Disorder - Recombinant Enzyme to Target LRP1 for Lysosomal Storage Disorder - RGI-5000 - SBLSD-3 - SBLSD-4 - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecules for GM1-gangliosidosis and Morquio B - Small Molecules for Lysosomal Storage Disorders - Stem Cell Therapy for Lysosomal Storage Disorder - UX-004 For more information visit http://www.researchandmarkets.com/research/jf...al_storage
FATE: 1.89 (+0.06), SGMO: 5.51 (-0.41), FOLD: 5.45 (-0.46)
Nuo Therapeutics Announces Execution of Second Limited Consent With Deerfield Management Through December 17, 2015
GlobeNewswire - Mon Dec 07, 7:30AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that on December 4, 2015, it entered into a limited consent with Deerfield Management, L.P. and certain of its affiliates, to modify certain provisions of the credit facility agreement ("Facility Agreement"
between Nuo and Deerfield, as follows: Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/997zbq/coronary_artery) has announced the addition of the "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amarantus Bioscience Holdings, Inc. - AnGes MG, Inc. - AstraZeneca Plc - Bayer AG - Biosidus S.A. - Biscayne Pharmaceuticals, Inc. - Capricor Therapeutics, Inc. - Eagle Pharmaceuticals, Inc. - Eli Lilly and Company - Gilead Sciences, Inc. - Hemostemix Ltd - Human Stem Cells Institute - Juventas Therapeutics, Inc. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Lonestar Heart, Inc. - MedImmune, LLC - Merck & Co., Inc. - Miltenyi Biotec GmbH - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. - The Medicines Company - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/99...ary_artery
CAPR: 4.18 (-0.20), PSTI: 1.29 (-0.07), LLY: 74.33 (+0.39), EGRX: 36.37 (-3.03), GILD: 80.47 (-2.90), AZN: 27.86 (-1.43), MRK: 55.88 (-1.80)
Nuo Therapeutics Announces Execution of Limited Consent With Deerfield Management Through December 4, 2015
GlobeNewswire - Thu Nov 12, 7:24PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the execution as of November 11, 2015 of a limited consent with Deerfield Management, L.P. and certain of its affiliates pursuant to which the Deerfield Facility Agreement was modified to provide that:
Nuo Therapeutics Announces 3rd Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 7:24PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today reported financial results for the third quarter ended September 30, 2015 and provided a strategic and operational update.
Nuo Therapeutics to Hold Third Quarter 2015 Conference Call on Friday, November 13 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Nov 04, 7:30AM CST
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the third quarter of 2015 on Thursday, November 12, 2015, after the close of market.
Nuo Therapeutics Responds to Favorable CMS Hospital Outpatient Payment Final Ruling for Aurix System
GlobeNewswire - Mon Nov 02, 7:31AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the Aurix(TM) System reimbursement rate under the Hospital Outpatient Prospective Payment System (HOPPS) for the calendar year 2016 has been published by the Centers for Medicare and Medicaid Services (CMS). Aurix was placed in Ambulatory Payment Classification (APC) 5054 (Level 4 Skin Procedures) and will be reimbursed at a national average rate of $1,411 per application effective January 1, 2016. In the text of the ruling, CMS commented they believe the geometric mean cost of the services underlying Aurix is comparable to the geometric mean cost of APC 5054.
Nuo Therapeutics Executes Amended Licensing Agreement With Arthrex
GlobeNewswire - Tue Oct 20, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced it has executed an amended and restated license agreement with Arthrex, Inc., through which Arthrex has exercised its right to assume responsibility for the manufacture and supply of the Company's Angel(R) Concentrated Platelet Rich Plasma System (Angel), an option granted and contemplated in the original license agreement. Additionally, Nuo is retaining the underlying patents to Angel while transferring the as-defined product registration rights and obligations.
Global Intermittent Claudication Pipeline Review 2015 - 6 Companies & 6 Drug Profiles
M2 - Mon Oct 05, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/678332/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Intermittent Claudication, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intermittent Claudication and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cytokinetics, Inc. - DNAVEC Corporation - Kowa Company, Ltd. - LTT Bio-Pharma Co., Ltd. - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. Drug Profiles - ALD-301 - DVC1-0101 - K-134 - LT-0101 - PLX-PAD - tirasemtiv For more information visit http://www.researchandmarkets.com/research/67...termittent
CYTK: 9.04 (+0.05), PSTI: 1.29 (-0.07)
Global Stem Cell Umbilical Cord Blood Market 2015-2019
M2 - Thu Sep 24, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5r9dpb/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood Market 2015-2019" report to their offering. Public awareness of stem cell UCB banking is increasing due to the various awareness programs conducted. This is done with the motive of making people aware of the potential benefits of cord blood banking. It will result in social and economic benefits as well. At the events, the idea is to educate people about the importance of cord blood banking. This is vital because it can help in the improvement of the quality of life of many patients suffering from life-threatening diseases. Companies such as Americord and Viacord are promoting July as National Stem Cell Awareness month. Similarly, Precious Cells surveyed 1,000 families in UK with children under the age of 10, as part of the National Stem Cell Awareness Day on October 8, 2014. To increase the awareness of cord blood banking, Save the Cord Foundation is partnering with Bioinformant. Also, LifeCell is creating awareness among in India about the need for umbilical cord stem cell banking. These programs help in promoting awareness for present and future stem cell treatments. According to the report, UCB stem cells prove to be an effective treatment option for more than 80 diseases, such as cancer, immunodeficiency disorders, and blood disorders. Many of these diseases, which have no cure, can be treated effectively with the use of stem cells obtained from the umbilical cord. These stem cells travel to the site of damage and identify the defective cells. They then initiate a healing process and are thus used in the treatment. Since they are derived from the same individual, the risk of rejection can also be eliminated. Research is being carried out for the development of UCB stem cells as an effective treatment option for diseases such as diabetes, Alzheimer's disease, brain tumor, and heart failure. They can thus be used as a successful mode of treatment for many of life-threatening diseases. Key Topics Covered - Executive Summary - Introduction - Process of Collection, Processing, and Storage of Cord Blood Cells - Facts: Cord Blood Units - US FDA Approved Stem Cell UCB Product - Pipeline Analysis - Market Landscape - Market Segmentation by Application - Market Segmentation by Storage - Harmonization of Biobanking - Market Segmentation by End-user - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Global Stem Cell UCB Market: Key Takeaways - Key Vendor Analysis Companies Mentioned - Athersys - Caladrius Biosciences - Celgene - CHA Bio & Diostech - Cytori Therapeutics - Mesoblast - Nuo Therapeutics - Ocata Therapeutics - Opexa Therapeutics - Osiris Therapeutics - Pluristem Therapeutics - Teva Pharmaceuticals - United Therapeutics For more information visit http://www.researchandmarkets.com/research/5r..._stem_cell
OCAT: 8.47 (+0.01), OPXA: 4.00 (+0.13), PSTI: 1.29 (-0.07), CYTX: 2.02 (+0.02), UTHR: 102.11 (-3.17), OSIR: 5.18 (-0.32), CLBS: 0.55 (+0.02), CELGZ: 1.42 (-0.03)
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015
M2 - Wed Sep 23, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mlsnz6/chronic_coronary) has announced the addition of the "Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Human Stem Cells Institute - Lacer, S.A. - Nuo Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/ml...c_coronary
Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019 - Key Vendors are AstraZeneca, Bayer, Eli Lilly, Novartis, Pfizer & Sanofi
M2 - Thu Sep 17, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6skk9g/global_ischemic) has announced the addition of the "Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019" report to their offering. The global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019. The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. The market has huge growth opportunities for vendors because of the growing population of individuals with IHD. To capture maximum market shares and expand the focus area, vendors are investing more on R&D. According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases. The people with diabetes are three to four times more likely to develop CVDs than people without diabetes. Further, the report states that the availability of effective surgical treatments and the use of catheter based interventions pose a challenge to the growth of market. The need for specific therapeutics at the later stages of the disease leads to the increased reliance on stents and surgeries. IHD includes: - Angina pectoris - Myocardial infarction. Key Vendors - AstraZeneca - Bayer - Eli Lilly - Novartis - Pfizer - Sanofi Other Prominent Vendors - Actelion - Amgen - Baxter - Boehringer Ingelheim - Bristol-Myers Squibb - Daiichi-Sankyo - Eisai - F.Hoffmann-La Roche - Gilead Sciences - GlaxoSmithKline - Human Stem Cells Institute - Janssen Pharmaceuticals - Juventas Therapeutics - Lacer - Merck - Nuo Therapeutics - Ono Pharmaceutical - Pharmahungary Group - Resverlogix - Takeda Pharmaceutical Company - Taxus Cardium - The Medicines Company - United Therapeutics For more information visit http://www.researchandmarkets.com/research/6s...l_ischemic
GILD: 80.47 (-2.90), UTHR: 102.11 (-3.17), MRK: 55.88 (-1.80), AMGN: 146.45 (-5.82), LLY: 74.33 (+0.39), GSK: 40.80 (-1.76), BMY: 70.61 (-2.03), NVS: 77.10 (-3.57)
Nuo Therapeutics Launches Educational Program to Support Wound Care Centers in Transition to ICD-10
GlobeNewswire - Mon Sep 14, 7:30AM CDT
First Webinar for Wound Care Professionals to be held September 15 at 1:00 p.m. Eastern on http://www.woundsresearch.com/ICD10
Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 5.64 (-0.43), PFE: 33.97 (-0.62), AZN: 27.86 (-1.43), AMGN: 146.45 (-5.82), LLY: 74.33 (+0.39), STML: 6.99 (-0.11)
